CORD Submission to Pre-Budget Consultations on 2022 Budget: Ensure timely implementation of Rare Disease Drug Strategy and Re-Focus PMPRB
CORD & RDI Call for a UN Resolution on Addressing the Challenges of Persons Living with a Rare Disease (PLWRD) and their Families.
CORD responds to Health Canada’s Clinical Trials Regulatory Modernization Initiative
PMPRB Regulations: Use Delay to Get it Right for Canadian Patients. June 28, 2021 CORD emphatically supports the federal government’s recent decision to delay the implementation of the Patented Medicines Regulations to January 1, 2022
Paddle with a Purpose Fundraiser for CORD- William Aiello the Weather Anchor for CTV News Northern Ontario will be taking on a journey of stand up paddle boarding for 24h in memory of his brother in law, Mario La Valle.
Canadian Organization for Rare Disorders submission to PMPRB GMEP. The PMPRB wants to measure the impacts of its own rules?? We need a neutral third party to do this assessment. Read CORD’s submission
PMPRB bias against patients exposed / breach of duty of neutrality. Commissioning Donald J. Savoie to research and write a memorandum the Duty of Neutrality in the context of the PMPRB’s advocacy plan
CORD Letter to Justin Trudeau, Prime Minister of Canada & Patty Hajdu, Minister of Health. Subject: PMPRB Campaign to Discredit Patients and Others Who Do Not Agree with Them
Worst Fears Confirmed! PMPRB Engages in Advocacy Campaign Against Patients
Time to Jump Start Rare Disease Drug Strategy: Open Letter to Prime Minister and Federal Health Minister
Exciting news! CADTH Canadian Expert Drug Committee has recommended reimbursement of Reblozyl/Luspatercept for chronically transfused Beta-Thalassemia patients.
Canadian Organization for Rare Disorders Responds to CADTH Recommendation for SMA Gene Therapy. Gaping Hole for SMA Babies: Why Canada needs National Rare Drug Strategy NOW